Breaking News: Mydecine Innovations Group Bolsters Scientific Advisory Board Adding a Leading Neuroscientist and a Psychopharmacology Specialist | Financial Buzz

Breaking News: Mydecine Innovations Group Bolsters Scientific Advisory Board Adding a Leading Neuroscientist and a Psychopharmacology Specialist

Mydecine Innovations Group Inc.(OTC: MYCOF) (CSE: MYCO), is pleased to announce the addition of two key strategic advisors to the company’s Scientific Advisory Committee.

The new members of the science team will provide scientific expertise and corporate strategy support as Mydecine begins its R&D program at its Innovation Center in Denver, Colorado. The advisory committee will review/monitor/access specific protocols and serve as an advocate for the organization providing technical expertise and collaborating with team members to help shape the direction of the various research programs.

Vince Polito is a Research Fellow at Macquarie University and former Associate Investigator at the Australian Research Council Centre of Excellence in Cognition and its Disorders. Mr. Polito’s research aims to understand how self-monitoring changes, self-representation, sense of agency, belief formation and altered states of consciousness. Vince’s research has been profiled in The Guardian, BBC, Buzzfeed, Nine News, Vice and many others.

Last year Mr. Polito conducted one of the largest to date Microdosing of psychedelics studies. In this research his team investigated the short- and long-term effects of microdosing on wellbeing, cognition and agency. The study conducted was a systematic, observational investigation of individuals who microdose (regular ingestion of very small quantities of psychedelic substances). The study tracked the experiences of microdosing participants, who provided daily ratings of psychological functioning over a six-week period and completed a battery of psychometric measures tapping mood, attention, wellbeing, mystical experiences, personality, creativity, and sense of agency, at baseline and at completion of the study. Analysis of pre and post study measures revealed reductions in reported levels of depression and stress; lower levels of distractibility; increased absorption; and increased neuroticism.

Anton Gomez-Escolar is a Psychopharmacology expert based in Madrid, Spain. Mr. Gomez-Escolar has a technical understanding of neurobiology, psychopharmacology, psychedelics, nootropics, drug safety and clinical trial development. Mr. Gomez-Escolar has a Masters in Psychopharmacology from Spain’s largest university Complutense University of Madrid, including a Master Thesis on the topic of “Psychedelics in psychotherapy for the treatment of depression and addiction”, a Masters in International Relations by Griffith University from Australia, and many other diplomas including a certificate of Design and Interpretation of Clinical Trials from John Hopkins School of Public Health, a certificate in Drug Discovery, Development & Commercialization from UCSD and a certificate in Drug Use, Policy and Health from the University of Geneva.

Mr. Gomez-Escolar is the co-founder the Psychedelic Society of Madrid, attended and presented in many international conferences on the topic and has worked for the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), the official European Union drugs information agency as well as Laboratorios Equisalud, a leading laboratory in holistic phytotherapy and nutritional supplements.

Rob Roscow, CSO and Director commented: “Our Scientific Advisory Board provides Mydecine independent, expert, multi-disciplinary, and strategic advice on scientific programs, emerging health science issues and trends in the psychedelic medicine sector. We are actively expanding our operations and we are thrilled to add these two talented individuals to our growing team.”

About Mydecine Innovations Group

Mydecine Innovation’s Group is a life sciences company focused on the development and commercialization of products and services that contribute to improving overall health and wellbeing. Our mission is to create a healthier world through advanced technologies, natural products, and psychedelic derived medicines. We own a group of trailblazing companies that are focused on helping millions of people live better lives and our portfolio includes:

  • Sponsored Content Release

    FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For mydecine innovations group inc., video production, filming editing, news reporting, financial and corporate news dissemination, FinancialBuzz.com has been compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com.